Breaking News

IMBRUVICA Capsules Gain Approval in CLL

By Kristin Brooks | February 14, 2014

Catalent to provide commercial supply from Kansas City site

IMBRUVICA (ibrutinib) has been approved by the FDA as a single, oral agent for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. The drug was originally approved on November 13, 2013 for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
 
Catalent Pharma Solutions has been contracted by Pharmacyclics to provide drug product capsules of IMBRUVICA for commercial supply from its site in Kansas City, MO.

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks